A Form 4 filed on August 13, 2026 discloses that Bridgette P. Heller, a director of DexCom Inc. (NASDAQ:DXCM), sold 1,012 shares of common stock on August 12, 2026 pursuant to a pre-established 10b5-1 trading plan.

Key Highlights

  • Shares sold: 1,012 shares of DexCom common stock disposed of on August 12, 2026.
  • Sale price: $88.29 per share, according to the filing.
  • Trading plan: The sale was made pursuant to a 10b5-1 Plan adopted by Ms. Heller on August 14, 2025.
  • Remaining ownership: 29,570 shares of common stock beneficially owned directly following the transaction.
  • Unvested RSUs included: 5,575 unvested restricted stock units, granted May 28, 2026, are included in the post-transaction total.
  • RSU vesting terms: The restricted stock units will vest on the earlier of the one-year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders.

DexCom Director Heller's Share Sale and Beneficial Ownership Details

According to the Form 4 filed with the SEC, Bridgette P. Heller, identified as a director of DexCom Inc., disposed of 1,012 shares of common stock on August 12, 2026 at a price of $88.29 per share. The filing states that the transaction was carried out under a 10b5-1 Plan that Ms. Heller adopted on August 14, 2025, described in the filing as a plan that "allows the orderly disposition of shares owned by Ms. Heller."

Following the reported transaction, the filing discloses that Ms. Heller directly beneficially owns 29,570 shares of DexCom common stock. The filing notes that this total includes 5,575 unvested restricted stock units granted on May 28, 2026. Those units are reported to vest on the earlier of the one-year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders.

The Form 4 was signed by Jereme M. Sylvain as attorney-in-fact for Bridgette P. Heller and dated August 13, 2026. No derivative securities transactions were reported in Table II of the filing.

What Was Disclosed

The filing reports the sale of 1,012 shares of DexCom common stock by director Bridgette P. Heller at $88.29 per share on August 12, 2026, under a pre-adopted 10b5-1 plan, leaving her with 29,570 directly held shares, including 5,575 unvested restricted stock units.